Patent classifications
C07D409/14
Heterocyclic compound and organic light emitting device comprising the same
Provided is a novel heterocyclic compound of Chemical Formula 1: ##STR00001##
and to an organic light emitting device including the same.
Heterocyclic compound and organic light emitting device comprising the same
Provided is a novel heterocyclic compound of Chemical Formula 1: ##STR00001##
and to an organic light emitting device including the same.
Composition of matter for use in organic light-emitting diodes
The present disclosure relates to compounds capable of emitting delayed fluorescence and uses of these compounds in organic light-emitting diodes.
Composition of matter for use in organic light-emitting diodes
The present disclosure relates to compounds capable of emitting delayed fluorescence and uses of these compounds in organic light-emitting diodes.
Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof
Ebola virus and Marburg virus are filoviruses and are responsible for outbreaks that cause up to 90% fatality, including the recent outbreak in West Africa that has resulted in over 11,000 deaths. The present disclosure generally relates to novel arylnaphthalene compounds as a vacuolar-ATPase inhibitor that are useful for the treatment of various viral infections, including those infections caused by filoviruses. Pharmaceutical composition matters and methods of use are within the scope of this invention.
Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof
Ebola virus and Marburg virus are filoviruses and are responsible for outbreaks that cause up to 90% fatality, including the recent outbreak in West Africa that has resulted in over 11,000 deaths. The present disclosure generally relates to novel arylnaphthalene compounds as a vacuolar-ATPase inhibitor that are useful for the treatment of various viral infections, including those infections caused by filoviruses. Pharmaceutical composition matters and methods of use are within the scope of this invention.
INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION
Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over D catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.
INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION
Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over D catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.
HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING ELEMENT, AND METHOD FOR PRODUCING ORGANIC LIGHT-EMITTING ELEMENT
The present specification provides a heterocyclic compound represented by Chemical Formula 1, an organic light emitting device comprising the same, a composition for an organic material layer of an organic light emitting device, and a method for manufacturing an organic light emitting device.
HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING ELEMENT, AND METHOD FOR PRODUCING ORGANIC LIGHT-EMITTING ELEMENT
The present specification provides a heterocyclic compound represented by Chemical Formula 1, an organic light emitting device comprising the same, a composition for an organic material layer of an organic light emitting device, and a method for manufacturing an organic light emitting device.